2025-01-09 - Analysis Report
## Merck & Co Inc (MRK) Investment Report

**1. Performance Comparison & Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  Over the review period, MRK's cumulative return (64.84%) significantly underperformed the S&P 500 (VOO) which had a cumulative return of 115.41%.  The difference is -50.6%, placing it in the 11.8th percentile of its historical performance range relative to the S&P 500. This suggests MRK lagged behind the broader market.  The provided Alpha consistently shows negative values (-0.1), indicating underperformance relative to the market benchmark (S&P 500) across all the periods.  The high Beta values suggest significant market sensitivity.  While the company has shown periods of high CAGR, the overall performance relative to the benchmark is consistently negative.

**2. Recent Price Movement:**

* **Closing Price:** $99.85
* **5-Day Moving Average:** $99.78
* **20-Day Moving Average:** $99.60
* **60-Day Moving Average:** $101.13

The price is slightly above the 5-day and 20-day moving averages, suggesting a mild upward trend in the short term. However, it's below the 60-day moving average, indicating a potential longer-term downward trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 49.14 (Near neutral; neither overbought nor oversold)
* **PPO:** 0.17 (Positive, suggesting bullish momentum)
* **Relative Strength Change (20-day):** -0.2 (Short-term weakening)
* **Expected Return (2+ years):** 45.2% (This is an expected return above the S&P 500 benchmark. However, the source and methodology for this calculation are not provided, making it difficult to assess the reliability of this figure.)

The current price of $99.85 does not show any signs of a significant price jump or drop based on the provided data.  The combination of indicators suggests a relatively neutral short-term outlook, but a potentially positive long-term outlook, contingent upon the validity of the provided expected return figure.


**4. Recent Earnings Analysis:**

The provided earnings data reveals a mixed picture:

* **Revenue:** Revenue has generally increased over the reported periods, albeit with some fluctuations.
* **EPS:** EPS shows variability, with a significant drop in the most recent quarter ($1.25) compared to the previous quarter ($2.15). This suggests a potential concern.  Note that there is a duplicate entry for 2024-11-06.  It is unclear which entry is correct.  This inconsistency impacts reliable trend analysis.


**5. Financial Information Analysis:**

* **Revenue and Profitability:**  Revenue shows consistent growth, although the rate of growth fluctuates. Profit margins are generally high but show some variability, decreasing slightly in the most recent quarter.
* **Capital and Profitability:** Equity has generally increased, although there's a notable decrease from Q2 2024 to Q3 2024. ROE is highly volatile and even negative in Q4 2023. This inconsistency requires further investigation.


**6. News and Recent Issues:**

No recent news (within the past 2 days) or analyst opinions are provided to inform this section.  Information regarding market outlook is also absent.


**7. Overall Analysis:**

MRK's performance has lagged the S&P 500 considerably over the provided time horizon. While recent price action shows a slight short-term upward trend, the longer-term trend seems to be downward. Technical indicators offer a mixed signal.  Earnings show some inconsistencies and a recent drop in EPS, causing some concerns. Financial information demonstrates revenue growth but significant variability in profitability and return on equity.  The lack of recent news and a clear explanation for the projected return hampers a complete analysis. More information, particularly regarding the discrepancy in earnings data and the source of the expected return, is needed to form a conclusive opinion on MRK's investment potential.  The data provided highlights a need for further investigation before making investment decisions.

**8. Disclaimer:** This report is based solely on the data provided. It does not constitute financial advice.  Conduct thorough due diligence and consult with a financial advisor before making any investment decisions.
